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Abstract
βarrestin (βarr)-1 and -2 (βarrs) are universal G protein-coupled receptor adapter proteins that
negatively regulate cardiac β–adrenergic receptor (βAR) function via βAR desensitization &
downregulation. In addition, they mediate G protein-independent βAR signaling, which might be
beneficial, e.g. antiapoptotic, for the heart. However, the specific role(s) of each βarr isoform in
cardiac βAR dysfunction, the molecular hallmark of chronic heart failure (HF), remain unknown.
Furthermore, adrenal βarr1 exacerbates HF by chronically enhancing adrenal production, and
hence circulating levels of aldosterone and catecholamines. Herein, we sought to delineate specific
roles of βarr1 in post-myocardial infarction (MI) HF by testing the effects of βarr1 genetic deletion
on normal and post-MI cardiac function and morphology. We studied βarr1 knockout (βarr1KO)
mice alongside wild type (WT) controls under normal conditions and after surgical MI. Normal
(sham-operated) βarr1KO’s display enhanced βAR-dependent contractility and post-MI βarr1KO’s
enhanced overall cardiac function (and βAR-dependent contractility) compared to WT’s. Post-MI
βarr1KO’s also show increased survival, and decreased cardiac infarct size, apoptosis, and adverse
remodeling, as well as circulating catecholamines & aldosterone, compared to post-MI WT’s. The
underlying mechanisms are on one hand improved cardiac βAR signaling and function, as
evidenced by increased βAR density and pro-contractile signaling, via reduced cardiac βAR
desensitization due to cardiac βarr1 absence, and on the other hand decreased production leading
to lower circulating levels of catecholamines & aldosterone due to adrenal βarr1 absence. Thus,
βarr1, via both cardiac and adrenal effects, is detrimental for cardiac structure and function and
significantly exacerbates post-MI HF.
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Despite recent advances in its prevention and management, heart disease, such as
hypertension and post-myocardial infarction (MI) heart failure (HF), remains the leading
cause of death in the western world and new treatments are needed.1 The molecular
hallmark in chronic HF is cardiac β-adrenergic receptor (βAR) dysfunction due to increased
receptor desensitization and downregulation.2–6 βARs belong to the superfamily of G
protein-coupled receptors (GPCRs), which, upon agonist binding, activate the Gs protein-
adenylyl cyclase (AC)-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)
signaling pathway leading to increased inotropy and chronotropy in the heart.2 In chronic
HF though, there is a selective downregulation of cardiac β1ARs and significant functional
desensitization (G protein uncoupling) of the remaining membrane β1ARs and β2ARs, which
dramatically diminish cardiac adrenergic and inotropic reserves.3–6 These processes are
mediated at the molecular level by the βarrestins (βarrs), which exist in two distinct isoforms
(βarr1 and -2, also known as arrestin-2 and -3, respectively) in mammals, and are abundantly
expressed in the heart.7–9 βarrs bind agonist-activated cardiac βARs, terminating their G
protein-mediated signaling and targeting them for internalization, following receptor
phosphorylation by GPCR kinase (GRK)-2 (mainly), the main cardiac GRK that is
significantly elevated in HF.2,8–16 Consistent with their crucial role in cardiac βAR
desensitization, βarr1 knockout (KO) mice display enhanced cardiac contractile responses to
isoproterenol (a standard βAR full agonist) stimulation in vivo.17
In addition, the βAR-bound βarrs have been shown to elicit a second wave of G protein-
independent signals, some of which might be beneficial for the failing heart, e.g.
extracellular signal-regulated kinase (ERK) activation and epidermal growth factor receptor
(EGFR) transactivation, both of which can promote cardiac cell survival, proliferation,
etc.18–21 However, the actions of the two βarrs in vivo are rarely complementary; in fact,
they might even oppose each other’s effects in certain tissues/organs, including in the
cardiovascular system (e.g. vascular smooth muscle cells and cardiomyocytes).22,23 With
regard to the heart, the exact role of each βarr in cardiac βAR desensitization or G protein-
independent signaling is not presently known. The physiological hallmark of chronic HF is
the sustained hyperactivity of several neurohormonal systems, in particular the sympathetic
nervous (SNS) and the renin-angiotensin-aldosterone (RAAS) systems, accompanied by
elevated circulating levels of the catecholamines (CAs) norepinephrine (NE) and
epinephrine (Epi), and of aldosterone, respectively.9,14,15 All these circulating hormones
exert detrimental effects on the failing heart, leading both to diminished function and to
accelerated and aggravated adverse remodeling in chronic HF.24,25 The main source of these
circulating hormones is the adrenal gland and we have shown in previous studies that βarr1,
in particular, is a crucial mediator of adrenocortical aldosterone production,26,27 as well as
of adrenomedullary CA production (acting in concert with adrenal GRK2),28–30 both
normally and in post-MI HF in vivo.
Given that the specific roles of cardiac βarr1 in βAR (dys)function and signaling in HF have
never been investigated and also the crucial role this protein plays in the adrenals in
elevating the neurohormonal burden of the failing heart, we sought to investigate, in the
present study, the effects of its genetic deletion on cardiac function, both normally and in
post-MI HF. In order to study the (patho)physiological role(s) specifically of this βarr
isoform in vivo, we took advantage of the available βarr1KO mouse model17 and studied
these mice alongside age-matched wild type controls (of note, the double βarr1/2 KO mice
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are embryonic-lethal).9 We found that the absence of βarr1 from the heart and the adrenals
leads to significantly elevated cardiac function in post-MI HF, accompanied by improved
adverse remodeling, reduced neurohormonal activation and better cardiac βAR signaling and
function.
Materials and Methods
Experimental animals and surgical procedures
The animals in this study were handled according to animal welfare regulations and
protocols approved by the authors’ Institutional Review Boards. An expanded “Materials
and Methods” section is available in the Supplementary Material online, which includes
detailed methods on the following: animals and surgical procedures, echocardiography and
hemodynamics, ELISA measurements of hormones and cytokines, infarct size
measurements, TUNEL and Masson-Trichrome staining, real-time PCR, βAR density,
cAMP and SERCA activity measurements, and western blotting.
Statistical analyses
Data are generally expressed as mean ± SEM. Unpaired 2-tailed Student’s t test and one- or
two-way ANOVA with Bonferroni test were generally performed for statistical
comparisons, unless otherwise indicated. For most 3-group statistical comparisons Dunnett’s
test using SAS version 8.2 software was used, as well. For all tests, a p value of <0.05 was
generally considered to be significant.
Results
Cardiac function of normal and post-MI βarr1KO mice
In order to investigate the impact on cardiac function of the genetic deletion exclusively of
βarr1, we utilized the available global βarr1KO mouse model (Figure S1). These mice breed
normally, without any gross abnormalities and present no overt cardiovascular or other
phenotype.17 To induce HF, three-month-old male mice underwent surgical MI and were
studied alongside age-matched male WT mice. We first examined the cardiac function
parameters of these mice, both in sham and post-MI groups. Echocardiography revealed
that, although similar between the sham groups (a finding consistent with the results of a
previous study on these mice17), (basal) ejection fraction was severely diminished in WT
mice at 4 weeks post-MI, as expected, but significantly higher in the post-MI βarr1KO’s at
the same time point (Figure 1A & Table S1). Consistent with these findings, upon in vivo
catheterization for hemodynamic measurements, post-MI βarr1KO mice also show
significantly enhanced cardiac contractility, both basally and in response to isoproterenol
stimulation, compared to post-MI WT mice (Figure 1B & Table S1), even though left
ventricular end-systolic and end-diastolic pressures are similar between the two post-MI
groups upon maximal isoproterenol challenge (Table S1). Notably, isoproterenol-induced
contractility is elevated also in sham (normal) βarr1KO’s compared to sham WT’s (Figure
1B & Table S1), which is again consistent with the results of a previous study on these
mice.17 Taken together, these findings strongly indicate that cardiac βarr1 is a major
negative regulator of βAR-dependent contractility in vivo and that its absence leads to
significant attenuation of cardiac dysfunction post-MI.
Survival and neurohormonal status of post-MI βarr1KO mice
Next, we sought to further examine the phenotype of the post-MI βarr1KO mice. Kaplan-
Meier survival curves indicated a markedly lower (overall) mortality of the post-MI
βarr1KO’s compared to post-MI WT controls (p=0.012, Figure 2A). This was accompanied
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by significantly reduced elevations in the plasma circulating levels of the CAs NE and Epi in
post-MI βarr1KO’s compared to post-MI WT’s (Figure 2B), indicative of reduced overall
sympathetic activitation in post-MI HF βarr1KO mice. As for the other major cardiotoxic
hormone, aldosterone, post-MI βarr1KO’s, remarkably, failed to exhibit any
hyperaldosteronism (i.e. elevation of circulating aldosterone levels) whatsoever, in marked
contrast to post-MI WT’s, which, as expected, display severe hyperaldosteronism (Figure
2C). This finding strongly corroborates the essential role of adrenal βarr1 in post-MI HF-
associated hyperaldosteronism we have previously reported.26,27 Finally, and consistent
with these effects on circulating levels of catecholamines and aldosterone, post-MI
βarr1KO’s also display significantly lower mean arterial blood pressure (125 ± 4 mm Hg)
than post-MI WT’s (141 ± 5 mm Hg) at 4 weeks post-MI (p<0.05, n=5).
Cardiac apoptosis, dilatation and infarct size in post-MI βarr1KO mice
The increased survival of the post-MI βarr1KO’s prompted us to investigate the cardiac
apoptosis in these mice. Cardiac cellular apoptosis, as measured with the TUNEL assay in
the hearts of the post-MI mice, was found significantly reduced in βarr1KO’s compared to
WT mice at 24 hrs post-MI, which is consistent with the Kaplan-Meier survival results
(Figure 3A). In addition, cardiac dilatation was also decreased in the βarr1KO’s compared to
WT controls at 4 weeks post-MI (Figure 3B & Table S1), and, importantly, infarct size was
also significantly reduced in the βarr1KO hearts compared to control WT hearts at the same
post-MI time point (4 weeks) (Figure 3C & 3D). To exclude the possibility that differences
in the extent of the initial injury inflicted by our surgical MI method upon the two lines
might have been responsible for this result, infarct size at 24 hrs post-MI was also measured
and found indistinguishable between the two groups (Figure S2A & S2B). Taken together,
these results indicate that post-MI βarr1KO hearts have decreased apoptosis, dilatation, and
infact size, which might underlie their favorable overall survival phenotype.
Cardiac inflammation, fibrosis and adverse remodeling markers in post-MI βarr1KO mice
Next, we examined markers of post-MI cardiac inflammation and adverse remodeling in the
two animal groups. Levels of all three major pro-inflammatory cytokines, tumor necrosis
factor (TNF)-α (Figure 4A), interleukin (IL)-6 (Figure 4B), and IL-1β (Figure 4C), were
found significantly decreased in post-MI βarr1KO hearts compared to control WT hearts at 4
weeks post-MI, indicating decreased overall cardiac inflammation in the post-MI βarr1KO
mice. Moreover, cardiac fibrosis, as measured with Masson-Trichrome staining, was also
markedly decreased in the post-MI βarr1KO mice compared to post-MI WT controls (Figure
4D & 4E). Finally, mRNA expression of all major adverse remodeling-associated
biomarkers, i.e. collagen synthesis (Figure 4F), B-type natriuretic peptide (BNP) (Figure
4G), atrial natriuretic factor (ANF) (Figure S3A), and transforming growth factor (TGF)-β
(Figure S3B), was significantly reduced in the post-MI βarr1KO hearts compared to post-MI
WT hearts, strongly suggesting that adverse remodeling is markedly attenuated in post-MI
βarr1KO hearts.
Cardiac βAR density, signaling and function in post-MI βarr1KO mice
In an effort to dissect the molecular mechanisms underlying the dramatic effect of the
absence of βarr1 on cardiac contractile function, we also investigated several aspects of
cardiac βAR signaling and function in the two post-MI groups. Consistent with the
phenotypic and functional data, total βAR density in the post-MI βarr1KO hearts was
significantly higher compared to post-MI WT hearts, which display marked βAR
downregulation post-MI, as expected (Figure 5A). This attenuated βAR downregulation in
post-MI βarr1KO hearts was accompanied by preserved total cAMP levels, again in sharp
contrast with the WT hearts whose cAMP content is dramatically diminished post-MI
(Figure 5B). Given that cAMP is the most critical mediator of cardiac βAR pro-contractile
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signaling,2,15 this result strongly indicates that the absence of cardiac βarr1 is sufficient to
restore βAR-dependent contractility in post-MI HF. Another important component of the
cardiac contractile machinery regulated by βARs is sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA)-2a.31 SERCA activity was also found significantly increased in post-MI
βarr1KO hearts compared to post-MI WT hearts (Figure 5C), thus providing another line of
evidence for the increased contractile function of post-MI βarr1KO hearts. Of note though,
cardiac SERCA activity of βarr1KO’s appears elevated also in the normal (sham) groups
(Figure 5C), indicating that cardiac βarr1 might affect the cardiac contractile machinery
even under normal conditions (no HF). Finally, since cardiac βarrs, and in particular βarr2,
have been shown to mediate EGFR transactivation from the β1AR upon the latter’s
phosphorylation by GRK5, an effect that is considered anti-apoptotic in the heart,18 we also
examined levels of EGFR transactivation in the post-MI hearts of βarr1KO’s and WT’s after
acute stimulation with isoproterenol in the presence of ICI-118,551 (a β2AR-selective
antagonist) in vivo (in order to activate the β1ARs only). Western blotting for phospho-
Tyr845-EGFR (active EGFR) in cardiac extracts from these mice revealed significantly
elevated EGFR transactivation in βarr1KO hearts compared to WT hearts at 24 hrs post-MI
(and also in sham hearts) (Figure 5D & 5E), suggesting that cardiac βarr1 inhibits (rather
than promotes) this β1AR-induced EGFR transactivation in the heart. Finally, in an effort to
better dissect the relative contributions of cardiac vs. adrenal βarr1 on the observed
phenotypes of the mice of the study, we overexpressed the known βarr1 inhibitor mini-gene
βarr1ct27 specifically in the hearts of post-MI WT mice, in order to inhibit cardiac (only)
βarr1 in vivo, and studied these hearts alongside control post-MI WT hearts receiving
adenovirus encoding green fluorescent protein (GFP) at the time of MI. As shown in Figure
S4, cardiac βarr1 inhibition with βarr1ct led to significant improvements in cardiac βAR
density (Figure S4A) and cAMP accumulation (Figure S4B) at 4 weeks post-MI, indicating
improved cardiac adrenergic and inotropic reserves, as expected; however, no significant
changes in circulating catecholamines of the post-MI WT mice were observed with cardiac
βarr1ct at 4 weeks post-MI (Figure S4C), indicating that catecholamine production/secretion
is mediated by adrenal (rather than cardiac) βarr1.
Discussion
βarr1 (and to a lesser extent βarr2) are abundantly expressed throughout the cardiovascular
system7–9 and regulate the vast majority of cardiovascular GPCRs, including cardiac βARs,
cardiac and adrenocortical angiotensin II (AngII) type 1 receptors (AT1Rs), adrenal and
central SNS α2ARs, etc.9,32,33 Their importance in cardiovascular (and other systems’)
biology is evidenced by the fact that the double βarr1/2 KO mouse is embryonic-lethal,32,33
Their actions on the heart have been attributed to both their functions as receptor
desensitizers/internalizers and as G protein-independent signal transducers.9,32 However,
and especially for their latter function, the exact in vivo roles of each cardiac βarr isoform in
GPCR-dependent signal transduction are currently unknown. In the present study, we were
able to delineate the cardiovascular phenotype of βarr1KO mice in post-MI HF, along with
its associated underlying molecular signaling mechanisms. Specifically, we found that the
absence of βarr1 from the heart leads to significantly better overall cardiac function in post-
MI HF, dramatically increased cardiac βAR-dependent cardiac function both physiologically
and in post-MI HF, and significantly attenuated adverse remodeling, apoptosis,
inflammation and infarct size, leading to improved overall survival post-MI. At the same
time, absence of βarr1 from the adrenal gland leads to a dramatically improved
neurohormonal profile of the failing post-MI heart, with reduced circulating catecholamine
and aldosterone levels. Finally, cardiac βAR signaling and function are dramatically
elevated in the post-MI βarr1KO mice, translating into markedly improved cardiac
adrenergic and inotropic reserves.
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Thus, βarr1 appears to be the single most important negative regulator of βAR-dependent
pro-contractile signaling and function, via the classical processes of desensitization and
downregulation of the cardiomyocyte βAR content, and its absence results in dramatically
elevated βAR-dependent contractility, both normally and after MI, and in almost restored
functional βAR number and cAMP-mediated signaling post-MI, i.e. in dramatically
improved β-adrenergic and inotropic reserves of the failing heart. Consistent with this,
cardiac SERCA activity is also markedly elevated in post-MI βarr1KO’s compared to
control WT mice. Of note however, SERCA activity is also significantly elevated in normal
(sham) βarr1KO mice, suggesting that the effects of cardiac βarr1 on SERCA activity extend
beyond (merely) βAR desensitization. Indeed, current investigations suggest that cardiac
βarr2 directly interacts with SERCA2a, promoting its SUMOylation and increasing its
activity,34 and that this is actually opposed by βarr1 (Lymperopoulos, A., unpublished data).
On the other hand, βarr2 appears unable to compensate for the absence of βarr1 for any of
these effects in vivo (and it is not compensatively upregulated, either; data not shown & Ref.
17). Taken together, these phenotypic findings strongly suggest that the βarr1 isoform is the
salient βarr responsible for βAR desensitization and downregulation in the heart (Figure 6),
processes whose dramatic elevation constitutes a molecular hallmark of chronic HF2,3,5.
Therefore, prevention of the interaction of βarr1 with cardiac βARs, which is achieved
(indirectly) via cardiac GRK2 inhibition with βARKct for instance,13,15,35 might be
beneficial as a positive inotropic therapy for HF (Figure 6).
It is now well known and documented that βarrs, in addition to the original biological role
ascribed to them as terminators of G protein-dependent signaling by GPCRs, can also serve
as signal transducers in their own right independently of G proteins.32,33 Indeed, specifically
in the heart, βarrs have been shown to mediate beneficial, anti-apoptotic and proliferation-
promoting signals from the β1AR (upon its phosphorylation by GRK5 and not GRK2
though) and from the mechanical stretch-activated AT1R via EGFR transactivation and
subsequent ERK phosphorylation/activation.18,36 In addition, they might even mediate pro-
contractile signaling from the AT1R in cardiac myocytes, an effect ascribed to βarr2 and
presumably inhibited by GRK2 and βarr1.23 We found that β1AR-induced EGFR
transactivation is significantly elevated in βarr1KO hearts in vivo, both in normal (sham)
conditions and (even more so) in post-MI HF, consistent with the apoptotic phenotype of the
βarr1KO hearts in vivo. This strongly suggests that cardiac βarr2 normally mediates this
beneficial, anti-apoptotic β1AR-dependent EGFR transactivation, whereas cardiac βarr1
opposes this signaling mechanism (Figure 6). Of course, studies in βarr2KO mice are
warranted to further validate this scenario. Another important aspect of HF pathophysiology,
in which the two βarr isoforms might exert differential or even opposing effects, is peri-
infarct area neoangiogenesis;37 in fact, given the difference observed in infarct size at 4
weeks post-MI (Figure 3C–D), this is quite likely and certainly warrants further
investigation in the future.
Finally, the neurohormonal profile of the post-MI βarr1KO mice confirms the essential roles
of adrenal βarr1 in: a) chronically elevated CA secretion in post-MI HF (via chronic
desensitization/downregulation of the sympatho-inhibitory α2ARs in the chromaffin cells of
the adrenal medulla) (Figure 6), and b) post-MI HF-associated hyperaldosteronism (via
increased AngII-dependent aldosterone synthesis and secretion in adrenocortical zona
glomerulosa cells) (Figure 6), which we have uncovered over the past several years.26–30
Admittedly, the biggest limitation of the present study is the use of a global knockout model
which precludes any safe conclusions on the relative contributions of adrenal vs. cardiac
βarr1 on the observed phenotypic effects of the post-MI βarr1KO mice. Only development
of tissue-specific KO mice can provide definitive answers to this important question.
However, our data on post-MI WT mice having cardiac-specific blockade of βarr1 courtesy
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of cardiac-specific βarr1ct overexpression strongly suggest that cardiac βarr1 absence is
responsible for the observed improvements in the adrenergic and inotropic reserves of the
post-MI βarr1KO mice, while their vastly improved neurohormonal profile (i.e. lower
circulating catecholamine levels and complete absence of hyperaldosteronism) is (mainly)
due to βarr1 absence from the adrenal glands. Given the extensive cross-talk between the
two organs (heart-adrenals) and that aldosterone and catecholamines can be produced also in
the heart per se however,38,39 drawing of these conclusions warrants extreme caution.
Nevertheless, all of the above findings are clinically important: we report for the first time
that βarr1 is the βarr isoform mainly (if not exclusively) responsible for cardiac βAR
desensitization and downregulation in vivo, a hallmark abnormality in chronic HF. In
addition, βarr1 promotes elevation of the neurohormonal burden of the failing heart through
its actions in the adrenal gland, and seems to oppose several beneficial signaling effects of
its counterpart, βarr2, in the myocardium, such as EGFR transactivation and ERK signaling,
which lead to inhibition of apoptosis and inflammation and to promotion of cardiac survival.
Thus, βarr1 removal from both the heart and the adrenals results in significantly improved
cardiac function, structural remodeling, β-adrenergic and inotropic reserves, reduced
neurohormonal burden and increased cardiac and overall survival in post-MI HF. These
findings strongly suggest that inhibition of βarr1 activity towards βARs in the heart and
βarr1 blockade in the adrenals, either directly (with a pharmacological βarr1-specific
inhibitor or via siRNA knockdown) or indirectly (e.g. via blockade of GRK2, which
promotes association of βarr1 with cardiac βARs) might be a viable therapeutic strategy for
chronic post-MI HF treatment, with the potential also of complementing or enhancing the
benefits of β-blocker therapy, which is hampered by the adverse effect of negative inotropy.
Perspectives
The present study reports for the first time that cardiac βarr1 is the βarr isoform responsible
for cardiac βAR desensitization and downregulation in vivo, a hallmark molecular
abnormality in chronic HF. In addition, adrenal βarr1 promotes elevation of the
neurohormonal burden of the failing heart by mediating catecholamine secretion and
aldosterone synthesis and secretion in the adrenal medulla and cortex, respectively. Finally,
βarr1 seems to oppose several beneficial signaling effects of its counterpart, βarr2, in the
myocardium, such as EGFR transactivation and ERK signaling, which lead to inhibition of
apoptosis and inflammation and to promotion of cardiac survival. Thus, βarr1 removal from
both the heart and the adrenals results in significantly improved cardiac function, halted
adverse remodeling, elevated β-adrenergic and inotropic reserves, reduced neurohormonal
burden and increased cardiac and overall survival in post-MI HF. These findings strongly
suggest that inhibition of βarr1 activity towards βARs in the heart and βarr1 blockade in the
adrenals, either directly (with a pharmacological βarr1-specific inhibitor or via siRNA
knockdown) or indirectly (e.g. via blockade of GRK2, which promotes association of βarr1
with receptors) might be a viable therapeutic strategy for chronic post-MI HF treatment.
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Refer to Web version on PubMed Central for supplementary material.
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Non-standard abbreviations and acronyms
MI myocardial infarction
HF heart failure
AR adrenergic receptor
GPCR G protein-coupled receptor
AC adenylyl cyclase
PKA protein kinase A
GRK GPCR kinase
βarr beta-arrestin
KO knockout
EGFR epidermal growth factor receptor
ERK extracellular signal-regulated kinase
SNS sympathetic nervous system
CA catecholamine
NE norepinephrine
Epi epinephrine
WT wild type
TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
TNFα tumor necrosis factor alpha
IL interleukin
cAMP 3′-5′ adenosine monophosphate (cyclic adenosine monophosphate)
SERCA sarco(endo)plasmic reticulum Ca2+-ATPase
AngII angiotensin II
AT1R AngII type 1 receptor
siRNA small interfering RNA
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Novelty and Significance
What Is New?
• βarr1 (rather than βarr2) is the βarr isoform responsible for βAR desensitization
and downregulation in vivo in the heart, a hallmark molecular abnormality in
chronic HF.
• βarr1 in the adrenals is absolutely essential for post-MI hyperaldosteronism and
catecholamine elevation in vivo, thereby heightening the neurohormonal burden
of the failing heart.
• Cardiac βarr1 also counters some beneficial effects of βarr2 in the myocardium,
e.g. anti-apoptosis and suppression of inflammation.
What Is Relevant?
• Adrenal βarr1 can promote hyperaldosteronism and sympathetic hyperactivity,
two neurohormonal mechanisms that contribute significantly to the development
of hypertension and HF.
• Pharmacological or genetic βarr1 inhibition in vivo, at least in the adrenals and
in the heart, might be a valid anti-hypertensive and anti-HF treatment strategy.
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Summary
Blockade of βarr1 activity in both the heart and the adrenal gland might be of therapeutic
value for halting or even reversing post-MI HF progression.
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Figure 1.
(A) Ejection fraction (EF) % of sham-operated (sham) or of 4-week post-MI (MI) βarr1KO
and WT mice. *, p<0.05, vs. either Sham; **, p<0.05, vs. WT MI; n=7 mice/group. (B)
Basal and maximal dose (333 ng/kg) of isoproterenol (Max. Iso)-stimulated +dP/dtmax
responses of these mice. *, p<0.05, vs. WT Sham-Max. Iso; #, p<0.05, vs. either Sham; **,
p<0.05, vs. WT MI-Max. Iso; ^, p<0.05, vs. WT MI-Basal; n=5 mice/group.
Bathgate-Siryk et al. Page 13
Hypertension. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
(A) Kaplan-Meier survival curves of the 4 groups of the study: sham-operated (Sham) and
post-MI (MI) βarr1KO and WT mice. p=0.012 between MI WT and MI βarr1KO; n=15
mice/group for sham, 37 mice/group for MI mice. (B) Plasma circulating NE and Epi levels
in sham-operated (Sham) or in 4-week post-MI (MI) βarr1KO (KO) and WT mice. *,
p<0.05, vs. Sham-either genotype; ^, p<0.05, vs. WT MI; n=6 mice/group. (C) Serum
aldosterone levels in these mice. *, p<0.05, vs. all other groups; n=6 mice/group.
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Figure 3.
(A) Apoptotic cell death at 24 hrs post-MI in βarr1KO (KO) and WT mice, as measured by
TUNEL performed in the border zone of the infarct. Representative images of TUNEL-
positive nuclei are shown (left), along with their quantitation (right). No difference in rate of
apoptosis in the remote zone was found (data not shown). *, p<0.05, vs. either Sham; #,
p<0.05, vs. WT MI; n=6 hearts/group. (B) Left Ventricular End Diastolic Diameter
(LVEDD) of these mice at 4 weeks post-MI or post-sham operation. #, p<0.05, vs. either
Sham; *, p<0.05, vs. WT MI; n=7 mice/group. (C–D) Infarct size at 4 weeks post-MI.
Representative triphenyltetrazolium chloride (TTC)–stained cardiac cross-sections are
shown in (C), and average left ventricular (LV) infarct size, expressed as % LV infarction
and measured from 6 mice/group, is shown in (D). **, p<0.05, vs. WT MI.
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Figure 4.
(A–C) Levels of pro-inflammatory cytokines TNFα (A), IL-6 (B), and IL-1β (C), measured
in serum of intra-cardiac blood from βarr1KO (KO) and WT mice at 4 weeks post-MI (MI)
or post-sham operation (Sham). *, p<0.05, vs. all other groups; **, p<0.05, vs. WT Sham;
n=5 mice/group. (D–E) Cardiac fibrosis staining in the 4-week post-MI mice. Blue denotes
collagen fibers, red denotes muscle fibers, and black represents cell nuclei. Representative
images are shown in (D) and quantification of the % fibrotic area in (E). *, p<0.05; n=5
hearts/group. (F–G) Heart mRNA levels of Collagen-1α1 (Col-1α1) (F) and of brain
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natriuretic peptide (BNP) (G) in these mice. #, p<0.05, vs. either Sham; *, p<0.05, vs. WT
MI; n=6 hearts/group.
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Figure 5.
(A) βAR density in cardiac plasma membranes of sham-operated (Sham) or of 4-week post-
MI (MI) βarr1KO (KO) and WT mice. *, p<0.05, vs. all other groups; n=5 hearts/group. (B)
Steady-state total cAMP levels in cardiac homogenates purified from these mice. *, p<0.05
vs. all other groups; n=5 hearts/group. (C) Cardiac SERCA activity measured in membrane
homogenates from the hearts of these mice. *, p<0.05, vs. WT Sham; **, p<0.05, vs. WT
MI; n=5 hearts/group. (D–E) Cardiac EGFR transactivation in these mice. Representative
western blots in total cardiac protein extracts for phospho-Tyr845-EGFR or total EGFR
(loading control) are shown in (D) and their densitometric quantitation in (E). Relative
EGFR transactivation was calculated by comparing the ratios of phospho-EGFR to total
EGFR for each sample. *, p<0.05, vs. either WT; **, p<0.05, vs. KO Sham; n=5 hearts/
group.
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Figure 6.
Schematic illustration of the cardiac (left) and adrenal (right) signaling mechanisms
underlying the effects of βarr1 on cardiovascular function. Gs: stimulatory G protein; P:
Phosphorylation; α2AR: alpha2-adrenergic receptor; AT1R: Angiotensin II type 1 receptor;
CA: Catecholamine. See text for details and all other molecular acronym descriptions.
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